Literature DB >> 29264971

Evolution of cancer treatment and evolving challenges.

Lynne Nakashima1.   

Abstract

This article will provide an overview of the evolving nature of cancer treatment, the benefits and challenges of these new treatments, and the leadership strategies required to manage the evolution from a system perspective. The number and complexity of novel cancer therapies, while offering improved patient outcomes, has become a challenge for the healthcare system due to the high cost of these new therapies. In Canada, the implementation of the pan-Canadian Oncology Drug Review and the pan-Canadian Pharmaceutical Alliance helps to streamline the review and negotiating process and to ensure consistency across provinces. Strategies to support these processes include ensuring safe patient treatment, patient counselling, clinician education, and practice innovation.

Entities:  

Mesh:

Year:  2018        PMID: 29264971     DOI: 10.1177/0840470417722568

Source DB:  PubMed          Journal:  Healthc Manage Forum        ISSN: 0840-4704


  5 in total

Review 1.  FEZF1-AS1: a novel vital oncogenic lncRNA in multiple human malignancies.

Authors:  Changlong Shi; Li Sun; Yongsheng Song
Journal:  Biosci Rep       Date:  2019-06-25       Impact factor: 3.840

Review 2.  The prognostic value and mechanisms of lncRNA UCA1 in human cancer.

Authors:  Fei Yao; Qiang Wang; Qingming Wu
Journal:  Cancer Manag Res       Date:  2019-08-14       Impact factor: 3.989

Review 3.  TC2N: A Novel Vital Oncogene or Tumor Suppressor Gene In Cancers.

Authors:  Hanyang Li; He Fang; Li Chang; Shuang Qiu; Xiaojun Ren; Lidong Cao; Jinda Bian; Zhenxiao Wang; Yi Guo; Jiayin Lv; Zhihui Sun; Tiejun Wang; Bingjin Li
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

Review 4.  ZFAS1: A novel vital oncogenic lncRNA in multiple human cancers.

Authors:  Anbang He; Shiming He; Xuesong Li; Liqun Zhou
Journal:  Cell Prolif       Date:  2018-10-05       Impact factor: 6.831

5.  Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B.

Authors:  Ana Alvarez de Cienfuegos; Lawrence H Cheung; Khalid A Mohamedali; Timothy G Whitsett; Jeffrey A Winkles; Walter N Hittelman; Michael G Rosenblum
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.